Patients' characteristics
| Patient characteristics (N = 127) . | TFH (n = 76) . | Non TFH (n = 51) . | P . |
|---|---|---|---|
| Sex, male/female, n (%) | 41 (54)/35 (46) | 33 (65)/18 (35) | .272 |
| Age, median (range), y | 63 (29-83) | 55 (30-81) | .003 |
| Prior therapies, median (range), n | 2 (1-5) | 2 (1-5) | .327 |
| Time from diagnosis, median (range), mo | 12 (3-157) | 9 (3-152) | .417 |
| Ann Arbor, n (%) | |||
| I-II | 3 (4) | 6 (12) | .155 |
| III-IV | 73 (96) | 45 (88) | |
| PS, n (%) | |||
| 0/1 | 58 (76) | 37 (73) | .575 |
| 2 or more | 12 (16) | 10 (20) | |
| Missing | 6 (8) | 4 (7) | |
| LDH, n (%) | |||
| Normal | 29 (38) | 16 (31) | .420 |
| Elevated | 34 (45) | 26 (51) | |
| Missing | 13 (17) | 9 (18) | |
| IPI at HDACi start, n (%) | |||
| 0-2 | 26 (34) | 16 (31) | .695 |
| 3-5 | 36 (47) | 26 (51) | |
| NA | 14 (18) | 9 (18) | |
| Type of treatment, n (%) | |||
| Commercial | 50 (66) | 34 (67) | .918 |
| Investigational | 26 (34) | 17 (33) |
| Patient characteristics (N = 127) . | TFH (n = 76) . | Non TFH (n = 51) . | P . |
|---|---|---|---|
| Sex, male/female, n (%) | 41 (54)/35 (46) | 33 (65)/18 (35) | .272 |
| Age, median (range), y | 63 (29-83) | 55 (30-81) | .003 |
| Prior therapies, median (range), n | 2 (1-5) | 2 (1-5) | .327 |
| Time from diagnosis, median (range), mo | 12 (3-157) | 9 (3-152) | .417 |
| Ann Arbor, n (%) | |||
| I-II | 3 (4) | 6 (12) | .155 |
| III-IV | 73 (96) | 45 (88) | |
| PS, n (%) | |||
| 0/1 | 58 (76) | 37 (73) | .575 |
| 2 or more | 12 (16) | 10 (20) | |
| Missing | 6 (8) | 4 (7) | |
| LDH, n (%) | |||
| Normal | 29 (38) | 16 (31) | .420 |
| Elevated | 34 (45) | 26 (51) | |
| Missing | 13 (17) | 9 (18) | |
| IPI at HDACi start, n (%) | |||
| 0-2 | 26 (34) | 16 (31) | .695 |
| 3-5 | 36 (47) | 26 (51) | |
| NA | 14 (18) | 9 (18) | |
| Type of treatment, n (%) | |||
| Commercial | 50 (66) | 34 (67) | .918 |
| Investigational | 26 (34) | 17 (33) |
IPI, International Prognostic Index; LDH, lactate dehydrogenase.